Biomolecular aspects of depression: A retrospective analysis

Peacock, Brandon; Scheiderer, David J.; Kellermann, Gottfried

doi:10.1016/j.comppsych.2016.11.002

Cited by 29 publications

(20 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…where N i is the size of the group i, µ i is the mean of an investigated parameter in group i, σ 2 i is the variance of this parameter [13,75]. If an absolute value of d is between [0.2-0.5] the effect is small (Sm), [0.5-0.8] is a medium effect (Md), an absolute value between [0.8-1.2] indicates a large effect (Lg), and an absolute value greater than +1.2 is a very large effect (VL).…”

Section: Discussionmentioning

confidence: 99%

“…Archetype Movements Integration-focuses on the enhancement of the primary biomechanics of motor patterns (extension, flexion, rotation, stretching-compression, and other) giving support for structural aspect of numerous reflex patterns, development of automatic and consciously learned motor abilities and skills; also postural and motor control, with secondary improvement in the speed of perception, focusing, and memory, in sensory-motor integration, and cognitive functions [75].…”

Section: The Mnri Reflex Integration Therapy Modalitymentioning

confidence: 99%

See 1 more Smart Citation

The Impact of MNRI Therapy on the Levels of Neurotransmitters Associated with Inflammatory Processes

Tatarinova

Deiss²,

Franckle

et al. 2020

IJMS

View full text Add to dashboard Cite

The neurotransmitter levels of representatives from five different diagnosis groups were tested before and after participation in the MNRI®—Masgutova Neurosensorimotor Reflex Intervention. The purpose of this study was to ascertain neurological impact on (1) Developmental disorders, (2) Anxiety disorders/OCD (Obsessive Compulsive Disorder), PTSD (Post-Traumatic Stress disorder), (3) Palsy/Seizure disorders, (4) ADD/ADHD (Attention Deficit Disorder/Attention Deficit Disorder Hyperactive Disorder), and (5) ASD (Autism Spectrum Disorder) disorders. Each participant had a form of neurological dysregulation and typical symptoms respective to their diagnosis. These diagnoses have a severe negative impact on the quality of life, immunity, stress coping, cognitive skills, and social assimilation. This study showed a trend towards optimization and normalization of neurological and immunological functioning, thus supporting the claim that the MNRI method is an effective non-pharmacological neuromodulation treatment of neurological disorders. The effects of MNRI on inflammation have not yet been assessed. The resulting post-MNRI changes in participants’ neurotransmitters show significant adjustments in the regulation of the neurotransmitter resulting in being calmer, a decrease of hypervigilance, an increase in stress resilience, behavioral and emotional regulation improvements, a more positive emotional state, and greater control of cognitive processes. In this paper, we demonstrate that the MNRI approach is an intervention that reduces inflammation. It is also likely to reduce oxidative stress and encourage homeostasis of excitatory neurotransmitters. MNRI may facilitate neurodevelopment, build stress resiliency, neuroplasticity, and optimal learning opportunity. There have been no reported side effects of MNRI treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: The Mnri Reflex Integration Therapy Modalitymentioning

confidence: 99%

The Impact of MNRI Therapy on the Levels of Neurotransmitters Associated with Inflammatory Processes

Tatarinova

Deiss²,

Franckle

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Elevated levels of inflammatory markers were found to be associated with decreased urinary KYNA in MDD patients. 89 Interestingly, KYNA/3-hydroxykynurenine (3-HK) was also reported to negatively correlate with hippocampal activity during memory recall, and KYNA/quinolinic acid (QA) correlated with negative specific memory recall and with hippocampal and amygdala volume in MDD patients. 90,91 It might be hypothesized that the kynurenine pathway could participate in the impairment of cognitive functions observed in MDD by influencing glutamatergic transmission in brain structures associated with cognitive processes.…”

Section: Inflammation and Cognition In Major Depressive Disordermentioning

confidence: 99%

“…96 In individuals with BD, plasma CRP levels are negatively correlated with immediate memory, language, and attention. 97 Similarly, elevated levels of Impaired Hebbian plasticity + (89) ? + + (148,149) 0/ + (154)(155)(156) Impaired homeostatic plasticity + (143) ?…”

Section: Inflammation and Cognition In Bipolar Disordermentioning

confidence: 99%

Neuroinflammation and cognition across psychiatric conditions

2019

View full text Add to dashboard Cite

Cognitive impairments reported across psychiatric conditions (ie, major depressive disorder, bipolar disorder, schizophrenia, and posttraumatic stress disorder) strongly impair the quality of life of patients and the recovery of those conditions. There is therefore a great need for consideration for cognitive dysfunction in the management of psychiatric disorders. The redundant pattern of cognitive impairments across such conditions suggests possible shared mechanisms potentially leading to their development. Here, we review for the first time the possible role of inflammation in cognitive dysfunctions across psychiatric disorders. Raised inflammatory processes (microglia activation and elevated cytokine levels) across diagnoses could therefore disrupt neurobiological mechanisms regulating cognition, including Hebbian and homeostatic plasticity, neurogenesis, neurotrophic factor, the HPA axis, and the kynurenine pathway. This redundant association between elevated inflammation and cognitive alterations across psychiatric disorders hence suggests that a cross-disorder approach using pharmacological and nonpharmacological (ie, physical activity and nutrition) anti-inflammatory/immunomodulatory strategies should be considered in the management of cognition in psychiatry.

show abstract

“…Большое количество и разнообразие ос-новных эффектов мелатонина открывает важные перспек-тивы измерения его уровня как биомаркера с целью клини-ческого, профилактического и терапевтического примене-ния [12]. Результаты исследования (ретроспективный ана-лиз данных 6-летнего периода) показали, что в модели об-щей депрессии существует нарушение регуляции в синтезе и метаболизме катехоламинов, нейромедиаторов, мелато-нина и иммунологических белков [13]. Также было показа-но, что мелатонин поддерживает оптимальный митохонд-риальный мембранный потенциал и сохраняет митохонд-риальные функции.…”

unclassified

Influence chronopharmacology therapy methionine (melaxen) on the dynamics of sleep disturbance, cognitive and emotional disorders, brain-derived neurotrophic factor (BDNF) in patients with cerebral stroke in the early and late recovery periods

Костенко¹

2017

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

С нарушением цикла «сон-бодрствование», распро-страненность которого в популяции колеблется от 28 до 43%, тесно связывают клинику мозгового инсульта. Нару-шение хронобиологических ритмов, например сна, может привести к нейропсихологическим расстройствам. При различных депрессивных расстройствах нарушения ноч-ного сна отмечаются в 83-100% случаев [1]. Нарушение © Е.В. Костенко, 2017 e-mail: ekostenko58@mail.ru сна при мозговом инсульте является частым, но недооце-ненным симптомом, являясь как прямым следствием са-мой болезни, так и развивающейся вторично по отноше-нию к боли депрессии. Диссомния может оказывать зна-чительное влияние на когнитивные и физические функ-ции пациента, снижая эффективность восстановительно-го лечения и качество жизни [2]. Цель исследования. Изучить эффективность влияния хронофармакологической терапии мелатонином (мелаксен) на динамику нарушений сна, когнитивных и эмоциональных расстройств, нейротрофического фактора мозга (BDNF) с учетом уровня секреции мелатонина у пациентов с инсультом в раннем и позднем восстановительном периодах. Материал и методы. Обследованы 110 пациентов в восстановительном периоде инсульта, средний возраст -58,4±6,4 года. Пациенты были разделены на две группы, 1-ю составили 60 больных в раннем восстановительном периоде, 2-ю -50 пациентов в позднем восстановительном периоде. Пациенты наряду со стандартной схемой лечения получали мелаксен 3 мг/сут в течение 3 мес. Эффективность проводимой терапии оценивали на основании динамики нарушений сна, эмоционального статуса, динамики концентрации BDNF, уровня 6-сульфатоксимелатонина в моче. Результаты и заключение. Проведенное исследование продемонстрировало высокую эффективность применения мелаксена в реабилитации пациентов в раннем и позднем восстановительном периодах инсульта. Препарат достоверно повышал концентрацию BDNF, что коррелировало с улучшением сна, эмоциональным статусом, качеством жизни пациентов. Ключевые слова: инсульт, реабилитация, мелаксен, нарушение сна, депрессия, нейротрофический фактор мозга.Influence chronopharmacology therapy methionine (melaxen) on the dynamics of sleep disturbance, cognitive and emotional disorders, brain-derived neurotrophic factor (BDNF) in patients with cerebral stroke in the early and late recovery periods Objective. To study the efficacy of melaxen on the dynamics of sleep disturbance, cognitive and emotional disorders, BDNF and the level of secretion of melatonin (6-SOMT) in patients with stroke in the early and late recovery phase. Material and methods. One hundred and ten patients in the rehabilitation period of stroke (mean age of 58.4±6.4 years), including 60 patients in the early recovery phase (group 1) and 50 patients in the late phase (group 2), were studied. Patients received melaxen in dose of 3 mg/day for 3 months along with standard treatment. The efficacy of therapy was assessed by the dynamics of sleep disorders, emotional status, dynamics of serum BDNF levels, 6-SOMT concentration in the urine. Results and conclusion. The study has demonstrated the high ef...

show abstract

Biomolecular aspects of depression: A retrospective analysis

Abstract: This study serves to further elucidate the role of biomolecules in the regulation of affective disorders, such as depression. Resulting in providing a network of clinically relevant biomarkers to objectively assess and monitor general depression.

Cited by 29 publications

References 69 publications

The Impact of MNRI Therapy on the Levels of Neurotransmitters Associated with Inflammatory Processes

The Impact of MNRI Therapy on the Levels of Neurotransmitters Associated with Inflammatory Processes

Neuroinflammation and cognition across psychiatric conditions

Influence chronopharmacology therapy methionine (melaxen) on the dynamics of sleep disturbance, cognitive and emotional disorders, brain-derived neurotrophic factor (BDNF) in patients with cerebral stroke in the early and late recovery periods

Contact Info

Product

Resources

About